NEXI Company Profile and Key Details
NexImmune
Price Chart
Stock Price Today
NexImmune, Inc. (NEXI) stock remained unchanged at $0.00 a share on OTC. The stock opened at $0.00, fluctuating between $0.00 to $0.00 during the session.
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| May 29, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 400 |
| May 27, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 1.28K |
| May 26, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 159 |
| May 21, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 1.83K |
| May 14, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 540 |
| May 08, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 2.34K |
| Apr 28, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 640 |
| Apr 27, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 176 |
| Apr 23, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 1K |
| Apr 21, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 595 |
| Apr 02, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 192 |
| Mar 23, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 303 |
| Mar 16, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 925 |
| Feb 09, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 507 |
| Jan 13, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 1.2K |
| Jan 06, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 450 |
| Jan 02, 2026 | 0.00 | 0.00 | 0.00 | 0.00 | 100 |
| Dec 31, 2025 | 0.00 | 0.00 | 0.00 | 0.00 | 105 |
| Dec 30, 2025 | 2.17 | 2.17 | 0.00 | 2.17 | 8.44K |
| Dec 26, 2025 | 0.00 | 0.00 | 0.00 | 0.00 | 4.2K |
Contact Details
About Company
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Company Information
| Employees | 6 |
| Beta | 5.47 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
Frequently Asked Questions
Chief Executive Officer, Pres & Director
Mr. John Trainer M.B.A.
Chief Financial Officer
Dr. Jeffrey S. Weber M.D., Ph.D.
Chief Scientific Advisor, Co-Chairman of Scientific Advisory Board and Member of AI & ID SAB
Mr. Karen Haslbeck
Head of HR
Dr. Robert Douglas Knight M.D.
Chief Medical Officer
Dr. Daniel P. Bednarik
Senior Vice President of Molecular Engineering & Protein Design
Dr. Jerome Bernard Zeldis M.D., Ph.D.
Consultant
Dr. Jack A. Ragheb M.D., Ph.D.
Senior Vice President of Translational Science
Mr. Chad Rubin
Senior Vice President of Corporation Affairs
Dr. Mathias Oelke Ph.D.
Chief Scientific Officer
Mr. Matthew Schiller
Head of Bus. Devel.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep